Sign in
Taking people in United StatesPhase 1/2

Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)

Key facts

Who runs it
Timothy Yu
Where
Boston, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
10 people, planned
Started
Aug 2026
Expected to end
Dec 2036
Type of study
Interventional
Treatments tested
  • Antisense oligonucleotide targeting the ATM gene
Record updated
28 May 2026

Who can take part

Age
0 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Other criteria

  • INCLUSION/EXCLUSION CRITERIA:
  • Who can take part:
  • People with classic A-T confirmed by genetic testing
  • Must have a specific ATM gene change (c.7865C>T)
  • Must also have another ATM change that causes A-T; Who cannot take part:; People with health problems that make lumbar puncture unsafe:
  • Blood clotting or bleeding problems
  • Brain conditions raising pressure inside the head
  • Serious heart or breathing problems
  • Infection near the lower back; Other things doctors will check:
  • Overall health and stability
  • Any medicines that might cause problems
  • Past difficulties with lumbar punctures
  • Any other safety concerns

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 0 and 17 years old?

Where in United States

  • Boston Children's HospitalBoston, United StatesContact: Arya NewingtonTaking people

About the trial

What the trial wants to find out

This project aims to evaluate the safety and efficacy of precision genetic therapy for patients with Ataxia-telangiectasia (A-T), a rare neurodegenerative disease caused by mutations in the ATM gene. The investigators will conduct a clinical trial to study the safety and efficacy of intrathecal administration of atipeksen, a targeted genetic therapy that restores ATM gene function in A-T individuals bearing the recurrent ATM c.7865C>T variant. The aim of this study is to delay or forestall progression of neurologic symptoms in A-T and improving quality of life. Success will provide an empirical foundation for advancing additional precision genetic therapies for A-T and other neurodegenerative conditions.

The group in the trial

  • Phase 1/2 Study of Antisense Oligonucleotide Therapy for Treatment of Ataxia - TelangiectasiaTreatment being tested

    Individuals with genetically confirmed, classic ataxia telangiectasia with at least one copy of the ASO-amenable ATM variant NM\_000051.3:c.7865C\>T;p.Ala2622Val, will receive the ASO at the same dose.

    Treatment: Antisense oligonucleotide targeting the ATM gene

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2 Study of Antisense Oligonucleotide Therapy for Treatment of Ataxia-Telangiectasia
Criteria questions
Built from NCT07215416, who can take part
Record updated
28 May 2026